+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Enzymatic Wound Debridement Market Size, Share & Trends Analysis Report By End-use, By Type (Chronic Wounds and Acute Wounds), By Product (Collagenase Product, Papain Product, and Others), By Country and Growth Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 144 Pages
  • January 2024
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5925343
The Europe Enzymatic Wound Debridement Market would witness market growth of 6.0% CAGR during the forecast period (2023-2030).

Enzymatic wound debridement is a therapeutic process that employs proteolytic enzymes to digest and liquefy necrotic tissue in wounds. These enzymes exhibit a high degree of specificity, targeting only the devitalized components without causing harm to healthy tissue. The primary objective of enzymatic debridement is to create an optimal wound-healing environment by facilitating the removal of dead tissue, foreign debris, and bacteria. The meticulous removal of devitalized tissue is crucial for promoting healthy tissue regeneration and preventing complications associated with chronic wounds. It involves the application of specific enzymes, such as collagenase, papain, and bromelain, which possess proteolytic properties to break down non-viable tissue.

The escalating incidence of chronic wounds, including diabetic ulcers, pressure sores, and venous ulcers, has fueled the demand for advanced wound care solutions. Enzymatic debridement, with its targeted and efficient approach, has emerged as a preferred choice in managing these challenging cases. Chronic conditions such as diabetes, vascular diseases, and immunosuppression pose challenges to wound healing, necessitating interventions like enzymatic debridement to enhance the chances of successful recovery. The demographic shift towards an older population significantly drives the market's expansion.

Europe engages in international collaborations in medical research. This collaborative approach supports advancements in wound care and the findings from international studies. As per the International Diabetes Federation, in Germany, people with diabetes in the 1000s were 6,199.9 in 2021, which is expected to grow 6,519.7 in 2030. Diabetes is a major risk factor for the development of diabetic foot ulcers. As the prevalence of diabetes rises in Germany, there is a corresponding increase in the incidence of diabetic foot ulcers. It is often recommended for the management of these ulcers. Therefore, the factors mentioned above will propel the market growth in this region.

The Germany market dominated the Europe Enzymatic Wound Debridement Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $82.6 million by 2030. The UK market is exhibiting a CAGR of 5.1% during (2023 - 2030). Additionally, The France market would showcase a CAGR of 6.9% during (2023 - 2030).

Based on End-use, the market is segmented into Hospitals, Homecare, and Others. Based on Type, the market is segmented into Chronic Wounds (Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, and Others), and Acute Wounds (Burns, and Others). Based on Product, the market is segmented into Collagenase Product, Papain Product, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ConvaTec Group PLC, Smith & Nephew PLC, Molnlycke Health Care AB, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, Coloplast Group, Medline Industries, Inc., 3M Company, HARTMANN Group (Paul Hartmann AG) and MediWound Ltd.

Scope of the Study

Market Segments Covered in the Report:

By End-use
  • Hospitals
  • Homecare
  • Others
By Type
  • Chronic Wounds- Diabetic Foot Ulcers
  • Pressure Ulcers
  • Venous Leg Ulcers
  • Others
  • Acute Wounds
  • Burns
  • Others
By Product
  • Collagenase Product
  • Papain Product
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

  • ConvaTec Group PLC
  • Smith & Nephew PLC
  • Molnlycke Health Care AB
  • Integra LifeSciences Holdings Corporation
  • B.Braun Melsungen AG
  • Coloplast Group
  • Medline Industries, Inc.
  • 3M Company
  • HARTMANN Group (Paul Hartmann AG)
  • MediWound Ltd

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Enzymatic Wound Debridement Market, by End-use
1.4.2 Europe Enzymatic Wound Debridement Market, by Type
1.4.3 Europe Enzymatic Wound Debridement Market, by Product
1.4.4 Europe Enzymatic Wound Debridement Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. Europe Enzymatic Wound Debridement Market by End-use
4.1 Europe Hospitals Market by Country
4.2 Europe Homecare Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Enzymatic Wound Debridement Market by Type
5.1 Europe Chronic Wounds Market by Country
5.2 Europe Enzymatic Wound Debridement Market by Chronic Wounds Type
5.2.1 Europe Diabetic Foot Ulcers Market by Country
5.2.2 Europe Pressure Ulcers Market by Country
5.2.3 Europe Venous Leg Ulcers Market by Country
5.2.4 Europe Others Market by Country
5.3 Europe Acute Wounds Market by Country
5.4 Europe Enzymatic Wound Debridement Market by Acute Wounds Type
5.4.1 Europe Burns Market by Country
5.4.2 Europe Others Market by Country
Chapter 6. Europe Enzymatic Wound Debridement Market by Product
6.1 Europe Collagenase Product Market by Country
6.2 Europe Papain Product Market by Country
6.3 Europe Others Market by Country
Chapter 7. Europe Enzymatic Wound Debridement Market by Country
7.1 Germany Enzymatic Wound Debridement Market
7.1.1 Germany Enzymatic Wound Debridement Market by End-use
7.1.2 Germany Enzymatic Wound Debridement Market by Type
7.1.2.1 Germany Enzymatic Wound Debridement Market by Chronic Wounds Type
7.1.2.2 Germany Enzymatic Wound Debridement Market by Acute Wounds Type
7.1.3 Germany Enzymatic Wound Debridement Market by Product
7.2 UK Enzymatic Wound Debridement Market
7.2.1 UK Enzymatic Wound Debridement Market by End-use
7.2.2 UK Enzymatic Wound Debridement Market by Type
7.2.2.1 UK Enzymatic Wound Debridement Market by Chronic Wounds Type
7.2.2.2 UK Enzymatic Wound Debridement Market by Acute Wounds Type
7.2.3 UK Enzymatic Wound Debridement Market by Product
7.3 France Enzymatic Wound Debridement Market
7.3.1 France Enzymatic Wound Debridement Market by End-use
7.3.2 France Enzymatic Wound Debridement Market by Type
7.3.2.1 France Enzymatic Wound Debridement Market by Chronic Wounds Type
7.3.2.2 France Enzymatic Wound Debridement Market by Acute Wounds Type
7.3.3 France Enzymatic Wound Debridement Market by Product
7.4 Russia Enzymatic Wound Debridement Market
7.4.1 Russia Enzymatic Wound Debridement Market by End-use
7.4.2 Russia Enzymatic Wound Debridement Market by Type
7.4.2.1 Russia Enzymatic Wound Debridement Market by Chronic Wounds Type
7.4.2.2 Russia Enzymatic Wound Debridement Market by Acute Wounds Type
7.4.3 Russia Enzymatic Wound Debridement Market by Product
7.5 Spain Enzymatic Wound Debridement Market
7.5.1 Spain Enzymatic Wound Debridement Market by End-use
7.5.2 Spain Enzymatic Wound Debridement Market by Type
7.5.2.1 Spain Enzymatic Wound Debridement Market by Chronic Wounds Type
7.5.2.2 Spain Enzymatic Wound Debridement Market by Acute Wounds Type
7.5.3 Spain Enzymatic Wound Debridement Market by Product
7.6 Italy Enzymatic Wound Debridement Market
7.6.1 Italy Enzymatic Wound Debridement Market by End-use
7.6.2 Italy Enzymatic Wound Debridement Market by Type
7.6.2.1 Italy Enzymatic Wound Debridement Market by Chronic Wounds Type
7.6.2.2 Italy Enzymatic Wound Debridement Market by Acute Wounds Type
7.6.3 Italy Enzymatic Wound Debridement Market by Product
7.7 Rest of Europe Enzymatic Wound Debridement Market
7.7.1 Rest of Europe Enzymatic Wound Debridement Market by End-use
7.7.2 Rest of Europe Enzymatic Wound Debridement Market by Type
7.7.2.1 Rest of Europe Enzymatic Wound Debridement Market by Chronic Wounds Type
7.7.2.2 Rest of Europe Enzymatic Wound Debridement Market by Acute Wounds Type
7.7.3 Rest of Europe Enzymatic Wound Debridement Market by Product
Chapter 8. Company Profiles
8.1 ConvaTec Group PLC
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 SWOT Analysis
8.2 Smith & Nephew PLC
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional and Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Molnlycke Health Care AB
8.3.1 Company Overview
8.3.2 SWOT Analysis
8.4 Integra LifeSciences Holdings Corporation
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 B. Braun Melsungen AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 SWOT Analysis
8.6 Coloplast Group
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 SWOT Analysis
8.7 Medline Industries, LP
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Partnerships, Collaborations, and Agreements:
8.7.2.2 Approvals:
8.7.3 SWOT Analysis
8.8 3M Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 HARTMANN Group (Paul Hartmann AG)
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. MediWound Ltd
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 SWOT Analysis

Companies Mentioned

  • ConvaTec Group PLC
  • Smith & Nephew PLC
  • Molnlycke Health Care AB
  • Integra LifeSciences Holdings Corporation
  • B. Braun Melsungen AG
  • Coloplast Group
  • Medline Industries, Inc.
  • 3M Company
  • HARTMANN Group (Paul Hartmann AG)
  • MediWound Ltd

Methodology

Loading
LOADING...